Join Growin Stock Community!

Editas medicine, inc.EDIT.US Overview

US StockHealthcare
(No presentation for EDIT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EDIT AI Insights

EDIT Overall Performance

EDIT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EDIT Recent Performance

-5.81%

Editas medicine, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

EDIT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EDIT Key Information

EDIT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EDIT Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Price of EDIT

EDIT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EDIT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.05
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.63
PB Ratio
15.96
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-430.84%
Revenue Growth (YoY)
-24.90%
Profit Growth (YoY)
-24.90%
3-Year Revenue Growth
464.20%
3-Year Profit Growth
464.20%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.05
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.63
PB Ratio
15.96
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-430.84%
Revenue Growth (YoY)
-24.90%
Profit Growth (YoY)
-24.90%
3-Year Revenue Growth
464.20%
3-Year Profit Growth
464.20%

  • When is EDIT's latest earnings report released?

    The most recent financial report for Editas medicine, inc. (EDIT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EDIT's short-term business performance and financial health. For the latest updates on EDIT's earnings releases, visit this page regularly.

  • What is the operating profit of EDIT?

    According to the latest financial report, Editas medicine, inc. (EDIT) reported an Operating Profit of -24.55M with an Operating Margin of -325.44% this period, representing a growth of 62.62% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is EDIT's revenue growth?

    In the latest financial report, Editas medicine, inc. (EDIT) announced revenue of 7.54M, with a Year-Over-Year growth rate of 12,265.57%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does EDIT have?

    As of the end of the reporting period, Editas medicine, inc. (EDIT) had total debt of 78.72M, with a debt ratio of 0.39. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EDIT have?

    At the end of the period, Editas medicine, inc. (EDIT) held Total Cash and Cash Equivalents of 165.65M, accounting for 0.82 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EDIT go with three margins increasing?

    In the latest report, Editas medicine, inc. (EDIT) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -325.44%%, and net margin of -333%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EDIT's profit trajectory and future growth potential.

  • Is EDIT's EPS continuing to grow?

    According to the past four quarterly reports, Editas medicine, inc. (EDIT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EDIT?

    Editas medicine, inc. (EDIT)'s Free Cash Flow (FCF) for the period is -31.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 43.66% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.